Innovation has three lead compounds—Prurisol, Kevetrin and Brilacidin—with first-in-class potential in mid-to-late stage development that have proven safe and effective in treating a number of indications across various therapeutic areas.
In dermatology, the current focus is on managing Psoriasis with Prurisol. For cancer, the emphasis is on Ovarian Carcinomas, a gateway indication toward Kevetrin treating many other types of hematological malignancies and tumors. In the area of infectious disease, Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is the target indication. As to gastrointestinal conditions, a study is underway evaluating Brilacidin's anti-microbial and anti-inflammatory properties in treating Inflammatory Bowel Disease. Brilacidin is also being tested in Oral Mucositis.